Ginkgo biloba for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

Ginkgo biloba for Health & Longevity

Created on 06/15/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

A standardized leaf extract with a modest, symptom-level benefit in people who already have memory or thinking problems, plus possible lowering of inflammation. It does not prevent dementia in healthy people. Generally well tolerated; the main concern is bleeding, especially near surgery or with blood thinners. Low cost, but product quality varies. (Full Review)

Protocol

Standard Dose
240 mg/day
Standardized extract EGb 761 for cognitive indications; 120 mg/day common for circulatory support but weaker evidence
Titration
Start 120 mg/day
Increase to 240 mg/day over 1–2 weeks only if tolerated, to reduce gastrointestinal upset, headache, and dizziness
Timing & Dosing
With food
Single daily dose or split into two 120 mg doses; morning or midday often preferred over late evening
Time to effect
Cognitive Benefit
4–8 weeks
Cognitive and functional benefits emerge gradually and are assessed at ~6 months; not an acute same-day effect
Mood Symptoms
4–8 weeks
Reductions in depression rating scores reported at 4–8 weeks, mostly as an add-on in post-stroke populations
Full Evaluation
3–6 months
Evaluate benefit after ~3–6 months of continuous 240 mg/day use; absence of change by 6 months supports discontinuation

Benefits

Contraindications
  • Therapeutic anticoagulation (warfarin with target INR, or any direct oral anticoagulant)
  • Within ~2 weeks of scheduled surgery
  • Epilepsy or seizure history
  • Known ginkgo or poison-ivy-family allergy
  • Pregnancy or breastfeeding
    •
Key Interactions
  • Anticoagulants and antiplatelet drugs (warfarin, apixaban, rivaroxaban, dabigatran, clopidogrel, aspirin)
  • Over-the-counter medications (NSAIDs such as ibuprofen and naproxen, OTC aspirin)
  • Antiepileptic drugs (valproate, carbamazepine, phenytoin)
  • Other interacting prescription drugs (some statins, certain antidepressants such as SSRIs, efavirenz)
  • Supplement interactions (fish oil, vitamin E, garlic extract, Panax ginseng, curcumin)
    •

Risk & Side Effects

  • High: [risks_high]
    •
  • Medium: Increased bleeding risk; gastrointestinal and general adverse effects
    •
  • Low: Seizure risk in susceptible individuals; allergic and skin reactions
    •
  • Speculative: Liver and thyroid tumor signal from animal toxicology
    •

Monitoring

Marker Target Why
Cognitive test score (e.g., MoCA) Stable or improved vs. baseline Tracks the primary cognitive goal
C-reactive protein (hs-CRP) < 1.0 mg/L Gauges inflammation that ginkgo may lower
INR (if on warfarin) Per anticoagulation target (e.g., 2.0–3.0) Detects bleeding-risk shift from interaction
Platelet count & CBC Within standard normal range Baseline for bleeding-risk context
Lipid panel (incl. HDL-C) HDL-C > 50 mg/dL (women), > 40 mg/dL (men) Context for cardiometabolic effects
HbA1c (if diabetic) < 5.7% non-diabetic; individualized if diabetic Monitors blood-sugar effect, which is uncertain

Cadence: Reassess at ~4 weeks and 3 months, then every 6–12 months; closer attention to clotting parameters if anticoagulants are co-used or surgery is planned.

Qualitative Assessment

  • Subjective memory and word-finding ease
  • Mental clarity and processing speed in daily tasks
  • Mood and stress tolerance
  • Energy and absence of headache or dizziness
  • Any unusual bruising or bleeding (a stop signal, not a success marker)
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.